

DMB

Display Date	6.7.99
Publication Date	6.8.99
Certifier	Michael W. Self

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### Joint Meeting of the Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

---

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee.

*General Function of the Committees:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held July 20, 1999, 8:30 a.m. to 5 p.m.


*Location:* Holiday Inn, The Ballrooms, Two Montgomery Village Ave., Gaithersburg, MD.

*Contact Person:* Sandra L. Titus or Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, or e-mail TITUSS@CDER.FDA.GOV, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On July 20, 1999, the committees will jointly consider an over-the-counter, new drug application (NDA) 21-070, Flexeril® (cyclobenzaprine HCl, 5 milligrams tablets, three times a day, Merck and Co.), proposed to treat muscle spasms.

NM-2


*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 12, 1999. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on July 20, 1999. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 12, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to



present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 28, 1999



Jane E. Henney  
Commissioner of Food and  
Drugs

[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

BILLING CODE 4160-01-F

**CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL**

*Michael W. Bell*